US Patent allowance for PTSD discovery programme

AI SummaryClose X

Solvonis Therapeutics plc has received a Notice of Allowance from the United States Patent and Trademark Office for compounds within its SVN-SDN-14 Post-Traumatic Stress Disorder discovery programme, strengthening its intellectual property as a lead compound is expected in Q1 2026. This patent covers a novel chemical series designed to modulate serotonin, dopamine, and noradrenaline pathways with improved pharmacological control, addressing historical challenges in developing effective PTSD therapeutics. The company views this as a significant milestone that enhances both the scientific and commercial foundations of its PTSD programme.

Disclaimer*

UK 100

Latest directors dealings